Risk-Based Assessments Urged For Therapeutic Protein Products

Washington Drug Letter
A A
Manufacturers and clinical investigators developing therapeutic protein products, such as monoclonal antibody cancer drugs, are urged to adopt risk-based assessments of patient immune responses that could impair drug safety and efficacy, draft FDA guidance states.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00